Fortis Healthcare: NTK Appeals Tokyo Court Ruling in Daiichi Sankyo Case to High Court

Market snapshot: Northern TK Venture Pte Ltd (NTK), the promoter shareholder of Fortis Healthcare, has escalated its legal battle by appealing to the Tokyo High Court on September 24, 2026. This appeal challenges the Tokyo District Court's September 10, 2026 judgment which dismissed NTK's massive JPY 200 billion damages claim against Daiichi Sankyo.

Data Snapshot

• Northern TK Venture Pte Ltd, an indirect wholly-owned subsidiary of IHH Healthcare Berhad, maintains a 31.17% promoter stake in Fortis Healthcare.
• NTK's amended damages claim filed in Japan against Daiichi Sankyo stands at JPY 200 billion, equivalent to approximately ₹11,800 crore, asserting losses caused by the delayed 26% mandatory open offer.
• Fortis Healthcare registered Q1 FY26 consolidated revenue of ₹2,545 crore, showing a growth of 17.5% year-on-year, alongside a net profit after tax of ₹273 crore.

What's Changed

• NTK's long-running JPY 200 billion damages litigation against Daiichi Sankyo moves to the Tokyo High Court after a formal petition for appeal was submitted on September 24, 2026.
• The legal dispute shifts venues following the Tokyo District Court's September 10, 2026 judgment, which dismissed NTK's damages claims and ordered it to bear the costs of the litigation.
• Fortis Healthcare has launched a separate domestic legal challenge, filing a Special Leave Petition in the Supreme Court of India on September 16, 2026, to challenge a Delhi High Court order directing a forensic audit.

Key Takeaways

• The Tokyo High Court appeal keeps the multi-year legal battle between IHH Healthcare's subsidiary NTK and Daiichi Sankyo active, preventing a final resolution on the historical transactional dispute.
• The damages claim arises from allegations that Daiichi Sankyo inappropriately delayed IHH's 2018 open offer to increase its stake in Fortis Healthcare to 51% by obtaining status quo orders in Indian courts.
• Fortis Healthcare's management continues to reassure investors that the company's daily hospital operations and long-term expansion plans are fully insulated from the outcome of these shareholder litigations.

SAHI Perspective

For long-term investors, the appeal to the Tokyo High Court signifies that IHH Healthcare and NTK are unwilling to back down from recovering alleged regulatory and capital blockages caused by Daiichi Sankyo's intervention. Although the litigation represents a sentiment overhang, Fortis Healthcare as an operating business has virtually zero direct financial exposure to the Tokyo proceedings. The primary risk remains a structural capital risk, as the resolution of this dispute is key to unlocking IHH's path to executing its delayed open offer and consolidating its shareholding to 51%.

Market Implications

The legal filing on September 24, 2026, will likely maintain a neutral trading zone for Fortis Healthcare shares. Investors are balancing the company's solid operational results against the double-pronged legal overhang of the Japanese appeal and the domestic Supreme Court challenge regarding the forensic audit. As long as these litigations are active, speculative volatility around corporate structuring and open offer expectations will persist.

Trading Signals

Market Bias: Neutral

Strong operational metrics like the 17.5% YoY revenue growth in Q1 FY26 to ₹2,545 crore are counterbalanced by structural legal overhangs. The newly filed appeal in the Tokyo High Court ensures that shareholder litigation remains unresolved in the near term.

Overweight: Healthcare Facilities, Hospitals

Trigger Factors:

• Supreme Court of India decision on Fortis Healthcare's Special Leave Petition against the forensic audit.
• Admission of NTK's appeal and preliminary hearings at the Tokyo High Court.
• Timeline updates on the integration of the newly announced 400+ bedded super-specialty hospital in Ashok Vihar, Delhi.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian private hospital and healthcare services sector continues to see steady demand driven by expanding capacities and medical tourism. IHH Healthcare remains committed to the Indian market, stating plans to eventually merge its unlisted Gleneagles India operations with Fortis Healthcare, reinforcing the long-term consolidation trend in national corporate hospital networks.

Key Risks to Watch

• Prolonged administrative and compliance drag from the potential execution of the Delhi High Court's forensic audit if the Supreme Court dismisses Fortis' SLP.
• Continued delay in the mandatory open offer, preventing IHH Healthcare from infusing direct equity and raising its stake to 51%.

Recent Developments

On September 24, 2026, NTK filed an appeal in the Tokyo High Court against the dismissal of its damages claim. This followed Fortis Healthcare filing an SLP in the Supreme Court of India on September 16, 2026, to block a Delhi High Court-mandated forensic audit. Separately, on September 16, 2026, Fortis Hospotel entered into agreements to manage a new 400+ bedded super specialty hospital in Delhi.

Closing Insight

While the Tokyo High Court appeal prolongs a complex historical litigation, Fortis Healthcare's robust fundamental execution and domestic expansion remain the primary anchors for its valuation.

High Performance Trading with SAHI.